These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23652926)

  • 1. To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.
    Weiss C; Schulze B; Ottinger A; Rödel C
    World J Urol; 2014 Feb; 32(1):59-67. PubMed ID: 23652926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.
    Ryan CW
    J Oncol Pharm Pract; 2017 Jan; 23(1):43-55. PubMed ID: 26625878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
    Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.
    Felici A; Bria E; Tortora G; Cognetti F; Milella M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1545-57. PubMed ID: 23253221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
    Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
    Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of therapy for advanced renal cell carcinoma.
    Basso M; Cassano A; Barone C
    Urol Oncol; 2010; 28(2):121-33. PubMed ID: 19576800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
    Cohen RB; Oudard S
    Invest New Drugs; 2012 Oct; 30(5):2066-79. PubMed ID: 22327313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the management of advanced renal cell carcinoma.
    Garcia JA; Rini BI
    CA Cancer J Clin; 2007; 57(2):112-25. PubMed ID: 17392388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential use of targeted agents in the treatment of renal cell carcinoma.
    Hutson TE; Bukowski RM; Cowey CL; Figlin R; Escudier B; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):48-62. PubMed ID: 20705477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New agents and new targets for renal cell carcinoma.
    Philips GK; Atkins MB
    Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Rini BI
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.